Generic · GLP-1 class

Dulaglutide

The weekly GLP-1 behind Trulicity — a biologic with no biosimilar yet.

Drug class: GLP-1 receptor agonist
Brand names: Trulicity
Manufacturer: Eli Lilly
Drug classGLP-1 receptor agonist
Brand namesTrulicity
ManufacturerEli Lilly
How takenWeekly injection
Max dose4.5 mg / week
PrescriptionRequired — Rx only

What is Dulaglutide?

Dulaglutide is a weekly GLP-1 receptor agonist sold only as Trulicity. Eli Lilly brought it to market in 2014, and for years it was the highest-volume GLP-1 in the United States.

Unlike semaglutide and tirzepatide, dulaglutide never got a weight-management approval. It stays in the diabetes lane, where it competes on A1C reduction, ease of use, and the cardiovascular result from REWIND.

Because it is a fusion protein rather than a small peptide, it is regulated as a biologic — meaning any cheaper version would have to be an approved biosimilar, and none exists.

How it works

Dulaglutide links two GLP-1 analogue peptides to a modified human antibody Fc fragment. The Fc portion makes the molecule far too large for the kidneys to filter quickly, stretching the half-life to roughly five days.

The receptor effects are standard for the class: insulin release rises when blood sugar is high, glucagon falls, the stomach empties more slowly, and appetite drops modestly. The appetite signal is weaker than semaglutide’s, which is why the weight results are smaller.

Dosing schedule

Dulaglutide comes in four fixed-dose single-use pens; there is no dial to adjust:

DoseWhen
0.75 mg / weekStarting dose
1.5 mg / weekStandard maintenance dose
3 mg / weekStep up after 4+ weeks if needed
4.5 mg / weekMaximum dose

Results in clinical trials

~1.1–1.9 point A1C reduction; 12% fewer major cardiovascular events

The AWARD trials showed A1C reductions of roughly 1.1 to 1.9 points across doses. REWIND, the cardiovascular outcomes trial, found a 12% reduction in major adverse cardiovascular events over a median 5.4 years in a population that was mostly primary prevention. Weight loss averages 7 to 10 lbs at the highest dose.

Side effects

Common

  • Nausea
  • Diarrhea
  • Vomiting
  • Abdominal pain
  • Decreased appetite
  • Indigestion
  • Fatigue

Serious (rare)

  • Pancreatitis
  • Gallbladder disease
  • Kidney injury from dehydration
  • Severe hypoglycemia with insulin or sulfonylureas
  • Hypersensitivity reactions
Boxed warning: Boxed warning for thyroid C-cell tumors seen in rodent studies. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

How much does Dulaglutide cost?

With no biosimilar on the market, dulaglutide means paying for Trulicity:

RouteTypical cost
Trulicity (list price)~$990 / month
With insurance (diabetes diagnosis)$25–$100 / month copay
Lilly savings cardAs low as $25 / month (eligible commercial plans)
Medicare Part DCovered for diabetes; annual out-of-pocket capped under the IRA
Generic / biosimilarNone approved

Prices vary by clinic, dose, and location — always confirm directly. See real local pricing on our clinic listings.

Frequently asked questions

Why is there no generic dulaglutide?

Dulaglutide is a biologic — an engineered fusion protein, not a small molecule — so a competitor would have to file as a biosimilar, a longer and more expensive path. Combined with patent protection running toward the end of the decade, that puts realistic biosimilar entry in the 2030s.

Is dulaglutide good for weight loss?

Not particularly. It produces about 7 to 10 lbs at the top dose and has no weight-management approval. Semaglutide and tirzepatide are several times more effective and are what providers prescribe when weight is the target.

How does dulaglutide compare to semaglutide?

Head-to-head in SUSTAIN 7, semaglutide beat dulaglutide on both A1C and weight. Dulaglutide holds ground on pen simplicity and on REWIND’s primary-prevention cardiovascular data, which semaglutide’s diabetes trials did not replicate in the same population.

Related medications

Guides

Primary sources

  1. Trulicity prescribing informationEli Lilly
  2. REWIND cardiovascular outcomes trialThe Lancet

This page is for educational purposes only and is not medical advice. Dulaglutide is a prescription medication — talk to a licensed healthcare provider about whether it is right for you. GLPFinders is a directory service and does not prescribe, sell, or dispense medications.

Find a Dulaglutide Provider Near You

Compare website-confirmed clinics offering GLP-1 treatment in your city, including disclosed pricing when available.

Browse Clinics →